Multiple Sclerosis Drugs Market Report 2026

Multiple Sclerosis Drugs Market Overview

• Multiple Sclerosis Drugs market size has reached to $33.46 billion in 2025 • Expected to grow to $61.43 billion in 2030 at a compound annual growth rate (CAGR) of 13% • Growth Driver: Government And Non-Government Support Fueling Growth Of Multiple Sclerosis Drugs Market • Market Trend: Innovative Products In The Multiple Sclerosis Drug Market • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Multiple Sclerosis Drugs Market?

Multiple Sclerosis drug refers to medications that are designed to stop the progression of disability and disease relapses. These medications are referred to as ‘disease-modifying treatment’. These drugs target a protein on the surface of immune cells and reduce the number of white blood cells to help prevent MS relapses. The white blood cells' propensity for nerve injury may be reduced by this impact. The main drug classes of multiple sclerosis drugs is immunomodulators, immunosuppressants, interferons, and others. Immunomodulators are a class of drugs that primarily target pathways involved in the treatment of multiple myeloma and a few other cancers. The various routes of administration include oral drugs and parenteral drugs that are distributed through hospital pharmacies, retail pharmacies, and online stores.

What Is The Multiple Sclerosis Drugs Market Growth Forecast?

The multiple sclerosis drugs market size is expected to see rapid growth in the next few years. It will grow to $61.43 billion in 2030 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to development of novel monoclonal antibodies, expansion of oral disease-modifying therapies, integration of personalized medicine in ms treatment, rising investment in r&d for emerging therapies, growing adoption of digital health monitoring and telemedicine platforms. Major trends in the forecast period include rising adoption of disease-modifying therapies for multiple sclerosis, growth in personalized and targeted ms treatment approaches, expansion of hospital and retail pharmacy distribution channels, increasing preference for oral and parenteral routes of administration, emergence of novel immunomodulators, immunosuppressants, and monoclonal antibodies.

Global Multiple Sclerosis Drugs Market Segmentation

1) By Drug Class: Immunomodulators, Immunosuppressants, Interferons, Other Drug Classes 2) By Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Stores 3) By Route Of Administration: Oral Drugs, Parenteral Drugs Subsegments: 1) By Immunomodulators: Glatiramer Acetate, Fingolimod, Teriflunomide, Dimethyl Fumarate 2) By Immunosuppressants: Natalizumab, Alemtuzumab, Ocrelizumab 3) By Interferons: Interferon Beta-1a, Interferon Beta-1b 4) By Other Drug Classes: Sphingosine 1-Phosphate Receptor Modulators, Monoclonal Antibodies, Other Emerging Therapies

What Is The Driver Of The Multiple Sclerosis Drugs Market?

The growth of the multiple sclerosis drugs market is aided by support from the government as well as non-government organizations. The government and non-government organizations fund several schemes and programs to offer their support to enhance the quality of life of people affected with multiple sclerosis (MS). For instance, the government of Alberta in partnership with the Department of Economic Development, Trade, and Tourism in Canada invested $1 million towards the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo) to support the research and innovations to enhance understanding and treatment for MS disease. CanProCo is an initiative to consolidate the efforts of nearly 50 MS researchers from various disciplines across Canada. The initiative was further funded by the Canada Brain Research, Biogen Canada, and the MS Society of Canada, as well as Hoffmann-La Roche Limited (Roche Canada) to raise a total of $10 million. Appropriate financial support from the government and non-government organizations boosts the growth of the multiple sclerosis drugs industry.

Key Players In The Global Multiple Sclerosis Drugs Market

Major companies operating in the multiple sclerosis drugs market are Biogen Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Bayer HealthCare LLC, Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Acorda Therapeutics Inc., EMD Serono Inc., AbbVie Inc., Bayer Schering Pharma AG, Bristol-Myers Squibb Company, Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, Opexa Therapeutics Inc., Receptos Inc., Synthon Pharmaceuticals Inc., TG Therapeutics Inc., Alkermes plc, Amgen Inc., Atara Biotherapeutics Inc., Celgene Corporation, Genzyme Corporation

Global Multiple Sclerosis Drugs Market Trends and Insights

Major companies operating in the multiple sclerosis drugs market are focused on developing innovative solutions to improve treatment efficacy, enhance patient quality of life, and address the diverse needs of individuals living with multiple sclerosis. Innovative solutions refer to new and creative approaches, products, or technologies designed to effectively address specific challenges or problems. For instance, in September 2024, Genentech, a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for treating relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo is the first and only subcutaneous injection, administered by healthcare professionals, that is given twice a year and takes approximately 10 minutes, providing individuals with MS additional treatment options.

What Are Latest Mergers And Acquisitions In The Multiple Sclerosis Drugs Market?

In March 2024, Juvisé Pharmaceuticals, a France-based pharmaceutical company, acquired Actelion Pharmaceuticals Ltd. for an undisclosed amount. With this acquisition, Juvisé Pharmaceuticals aims to expand its portfolio and enhance patient care by acquiring global commercial rights to Ponvory for the treatment of relapsing multiple sclerosis outside the US and Canada. Actelion Pharmaceuticals Ltd.is a Switzerland-based pharmaceutical company that specializes in the discovery, development, and commercialization of innovative drugs.

Regional Insights

North America was the largest region in the global multiple sclerosis drug market in 2025. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Multiple Sclerosis Drugs Market?

The multiple sclerosis drug market consists of sales of lemtrada, novantrone, ocrevus, and tysabri. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Multiple Sclerosis Drugs Market Report 2026?

The multiple sclerosis drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the multiple sclerosis drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.